



Cutting-edge collaborative research

Scotland joins AstraZeneca's global genomics initiative in a partnership with NHS Scotland, Scottish Universities and industry partners

"This places Scotland at the heart of a major global programme and is testament to the strength of our clinical, health informatics and genomics research base, and appetite for industry partnership."

Shona Robison
*Cabinet Secretary -
Health & Sport, Scottish
Government*



A global pharmaceutical company with a major UK presence, AstraZeneca works to push the boundaries of science to deliver life-changing medicines.

AstraZeneca's Integrated Genomics Initiative

AstraZeneca's Integrated Genomics Initiative will leverage information from up to two million genomic sequences over 10 years. The goal is to identify rare genetic variations that are associated with disease and how different individuals respond to treatment.

The programme involves collaboration with world renowned partners including the **Wellcome Trust Sanger Institute** in the UK, **Human Longevity Inc.** in the USA and Finland's **Institute for Molecular Medicine**.

To discuss academic partnerships in Scotland contact Stephen Kelly, Ph.D., HSS Manager, NRS
stephen.kelly@nrs.org.uk • +44 141 951 5508 • Or visit www.nrs.org.uk

In Scotland, a range of collaborative initiatives bring together our single healthcare provider, the NHS, with academic researchers and industry partners.

The aim of **Stratified Medicine Scotland – Innovation Centre (SMS-IC)**, is to position Scotland as a global centre of excellence in precision medicine. The SMS-IC is the strategic initiative that brings together and facilitates interactions between healthcare, life sciences and academic organisations to deliver precision medicine programmes effectively and efficiently.

SMS-IC provides access for industry partners, like **AstraZeneca**, to a host of high-quality data assets and associated services. It also provides direct access to a network of world class clinical and academic institutions working at the leading edge of precision medicine research and real world application.



"I am delighted that AstraZeneca has chosen Scotland to partner with in this ground-breaking genomic and informatics venture. I believe that through this new partnership we, at the University of Glasgow, alongside all other Scottish partners, will be able to further develop this important area of medical research"

***Professor Dame Anna Dominiczak** Vice Principal and Head of the College of Medical, Veterinary and Life Sciences at the University of Glasgow*



"Working together with NHS Scotland, Scottish universities and Stratified Medicine Scotland will be a really important part of our strategy. This collaboration will provide access to consented genomic samples, electronic health records and importantly the ability to recall patients for deeper clinical investigation to help us better understand the underlying causes of disease"

***Mene Pangalos** Executive Vice President IMED Biotech Unit and Global Business Development, AstraZeneca*

www.nrs.org.uk



[@NHSResearchScot](https://twitter.com/NHSResearchScot)

communications@nrs.org.uk

NHS Research Scotland (NRS) is a partnership of Scottish NHS Boards and the Chief Scientist Office of Scottish Government. Registered Number: GB 236303. Registered address: The Golden Jubilee National Hospital, Fourth Floor East, Agamemnon St, Clydebank, G81 4DY.

Published by NHS Research Scotland. All rights reserved. Material contained in this publication may not be reproduced in whole or part without prior permission of NHS Research Scotland (or other copyright owners). Whilst every effort is made to ensure that the information given here is accurate, no legal responsibility is accepted for any errors, omissions or misleading statements.